pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

506 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1024Endpoints775BioPharma Dive297BioSpace214Fierce Biotech203onclive165raps74globenewswire health
therapy area
allOncology6024Rare Disease1430Cardiology1089Hematology1024Immunology997Vaccines901Pulmonology
  • Danske Bank corrects webpage to place English PDF under English version for share buy-back disclosure
    A correction notice was issued for Danske Bank A/S regarding the placement of an English PDF on its website. The original posting had both Danish and English PDFs attached under the Danish version…
    globenewswire health · 15d agoNeutral↗ source
  • Danske Bank corrects webpage to place English PDF in English section
    A correction has been issued for a previous notification concerning Danske Bank A/S. The original posting attached both Danish and English PDF files under the Danish version of the page. The corre…
    globenewswire health · 15d agoNeutral↗ source
← prev
page 6 of 21
next →
73
fda recalls47
fda medwatch37
fda press28
899
Psychiatry & CNS712
Ophthalmology420
Endocrinology & Metabolism380
Pain372
Infectious Disease353
  • Danske Bank corrects webpage to place English PDF under English version
    In a recent update, Danske Bank clarified a mistake on its transaction reporting page. The original notice had both the Danish and English PDF documents linked under the Danish version of the site.…
    globenewswire health · 15d agoNeutral↗ source
  • Danske Bank corrects website to relocate English PDF to appropriate page
    Danske Bank issued a correction notice indicating that an English PDF document has been moved to the English version of its website. The original announcement had attached both Danish and English…
    globenewswire health · 15d agoNeutral↗ source
  • Correction: English PDF for Danske Bank transaction disclosures moved to English webpage
    A correction notice has been issued for a Danske Bank disclosure on transactions by persons with managerial responsibilities. The update concerns the location of the English language PDF on the ban…
    globenewswire health · 15d agoNeutral↗ source
  • Danske Bank corrects placement of English PDF in transaction disclosure
    A correction notice was issued for Danske Bank A/S concerning the location of an English PDF file in its public disclosure. The original announcement had both the Danish and English PDFs attached…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank corrects webpage to place English PDF in English section
    A correction has been issued for a Danske Bank notification concerning the placement of PDF documents on its website. The original posting attached both the Danish and English versions of the PDF…
    globenewswire health · 15d agoNeutral↗ source
  • Danske Bank discloses share sales by APMH Invest under its buyback program
    On August 5, 2026, Danske Bank A/S filed a market‑abuse regulation report detailing changes in share ownership among its reporting persons. The filing notes that APMH Invest A/S, a shareholder, so…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank reports manager share transactions linked to ongoing buy-back program
    Danske Bank A/S filed a notification under the EU Market Abuse Regulation, disclosing transactions made by persons with managerial responsibilities. The filing notes that APMH Invest A/S is contin…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank reports share sale by APMH Invest under its buyback program
    Danske Bank A/S filed a regulatory disclosure on 5 August 2026 detailing a change in shareholdings linked to its EU‑mandated market‑abuse reporting requirements. APMH Invest A/S sold shares of Dan…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank reports ongoing share buy-back sales by APMH Invest under regulatory disclosure
    On 5 August 2026 Danske Bank A/S filed a notification under the EU Market Abuse Regulation describing transactions by persons required to report to the Danish FSA and Nasdaq Copenhagen. The bank d…
    globenewswire health · 15d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website to move English PDF to English page
    Danske Bank issued a correction notice about the placement of its PDF documents on its website. The original posting attached both the Danish and English PDFs under the Danish version of the page.…
    globenewswire health · 15d agoNeutral↗ source
  • Pathos AI acquires bispecific ADC from Alphamab and secures AstraZeneca partnership
    Pathos AI announced it will pay $125 million upfront for the rights to JSKN016, a bispecific TROP2/HER3 antibody‑drug conjugate from China’s Alphamab Oncology. The agreement also includes up to $2.…
    Fierce Biotech · 16d agoDealPositive↗ source
  • Amgen halts development of early-stage obesity drug AMG 513, shifting focus to phase-3 candidate MariTide
    Amgen announced it is stopping work on AMG 513, an early-stage obesity therapy, during its second-quarter earnings call. The decision follows a previous FDA clinical hold in early 2025 that was la…
    Fierce Biotech · 16d agoNegative↗ source
  • Expedition Therapeutics raises $115M Series B to fund phase 2 COPD trial of DPP1 inhibitor
    Expedition Therapeutics, backed by Sanofi, announced a $115 million Series B financing round. The round was led by General Atlantic with participation from RA Capital, Vivo Capital, and existing i…
    Fierce Biotech · 16d agoDealPositive↗ source
  • Lisata cuts 72% of workforce and sues Kuva after merger collapse
    Lisata, a solid tumor biotech, announced it is laying off roughly 72% of its employees, including its chief medical officer, as it reassesses its future. The cuts follow the collapse of a planned…
    Fierce Biotech · 16d agoLayoffsNegative↗ source
  • Merck’s anti‑TL1A antibody misses SSc‑ILD trial but hits primary endpoints in hidradenitis suppurativa
    Merck's anti‑TL1A monoclonal antibody, tulisokibart, was evaluated in two phase 2 studies. In the systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) trial, the primary endpoint was…
    Fierce Biotech · 16d agoNeutral↗ source
  • Icon partners with Anthropic to integrate Claude AI into clinical trial planning
    Icon, a contract research organization, announced a multi-year collaboration with Anthropic to bring the Claude AI system into its clinical trial operations. The partnership will combine Anthropic…
    Fierce Biotech · 16d agoDealPositive↗ source
  • Smith & Nephew lowers 2026 sales outlook as US knee implant revenue falls 7%
    Smith & Nephew announced a revision to its 2026 sales outlook, now expecting underlying revenue growth of about 4% versus the prior 6% target. The change follows a second‑quarter report showing re…
    Fierce Biotech · 16d agoEarningsNegative↗ source
  • Pfizer drops two obesity programs, including Metsera-derived GLP-1 candidate, in pipeline cleanout
    Pfizer announced it is removing two clinical‑stage obesity programs as part of its quarterly pipeline cleanout. The first program, MET-224o, is an oral ultra‑long‑acting GLP‑1 receptor agonist tha…
    Fierce Biotech · 16d agoNegative↗ source
  • KKR to acquire medtech maker Integer in $5.7 billion deal
    KKR announced an agreement to take Integer private for approximately $5.7 billion, offering $127 per share in cash to Integer stockholders. Integer, based in Plano, Texas, saw its shares rise abou…
    Fierce Biotech · 16d agoDealNeutral↗ source
  • Latigo Biotherapeutics targets non-opioid pain market with $247 M IPO
    Latigo Biotherapeutics announced details of its planned initial public offering, aiming to raise roughly $247 million to advance its pipeline of non-opioid pain treatments. The company intends to…
    Fierce Biotech · 16d agoDealPositive↗ source
  • Early Alert: Intraosseous Needle Set Issue from Becton Dickinson
    BD is recalling certain BD Intraosseous Vascular Access System Needle Sets due to difficulty removing the obturator (stylet) following placement.
    fda medwatch · 16d agoRegulatoryNeutral↗ source
  • Liebel-Flarsheim recalls OPTIRAY imaging contrast agent after detecting plastic, metal and glass particles
    Liebel-Flarsheim Company announced a recall of one lot of its OPTIRAY Imaging Bulk Package, a 350/500 mL vial of ioversol injection used for intra‑arterial and intravenous imaging. The recall was…
    fda medwatch · 16d agoCRLNegative↗ source
  • Danske Bank reports share sale by APMH Invest under its buyback program
    On August 4, 2026, Danske Bank A/S filed a market‑abuse regulation report detailing a change in share ownership. The filing shows that APMH Invest A/S sold a portion of its Danske Bank shares on a…
    globenewswire health · 16d agoRegulatoryNeutral↗ source